Observational Study to Evalute the Efficacy and Safety of Avastin (Bevacizumab) in Addition to Platinum-Based Chemotherapy for First-Line Treatment of Participants With Non-Small Cell Lung Cancer

Sponsor
Hoffmann-La Roche
Study ID
NCT03170284
Status
Completed

Conditions

  • Carcinoma, Non-Small-Cell Lung

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    Bevacizumab is prescribed by physicians as per SPC.

Study Details

The purpose of this study is to examine the efficacy of Bevacizumab in addition to platinum-based chemotherapy for first-line treatment of participants with advanced stage (IIIB/IV) non-small cell lung cancer (NSCLC) other than predominantly squamous cell histology.

Key Dates

First listed
May 31, 2017
Start date
Jun 17, 2008
Status verified
May 2017
Primary completion
Aug 1, 2012
Completion
Aug 1, 2012

Study Design

Enrollment
150 participants (actual)

Arms

  • Arm: Bevacizumab
    Participants with advanced (stage IIIB/IV) NSCLC other than predominantly squamous cell histology receiving Bevacizumab in accordance with the summary product characteristics (SPC) is observed.

Primary Outcome Measure

Time to Disease Progression [ Time Frame: up to 45 months ]

Related Studies